Thermo Fisher Scientific Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 39.21B | 44.91B | 42.86B | 42.88B | 44.56B | 3.9% | |
| Cost of Revenue | (19.58B) | (25.90B) | (25.66B) | (25.15B) | (27.78B) | 10.4% | |
Gross Profit | 19.63B | 19.01B | 17.19B | 17.73B | 16.78B | -5.4% | |
| Operating Expenses | |||||||
| Research & Development | (1.41B) | (1.47B) | (1.34B) | (1.39B) | (1.40B) | 0.5% | |
| Selling, General & Administrative | (7.91B) | (9.02B) | (8.41B) | (8.68B) | (7.27B) | -16.2% | |
| Depreciation & Amortization | (2.59B) | (3.38B) | (3.41B) | (3.11B) | (2.78B) | -10.6% | |
Operating Income (EBIT) | 10.32B | 8.53B | 7.45B | 7.66B | 8.11B | 5.8% | |
| Non-Operating Items | |||||||
| Interest Income | 43.00M | 272.00M | 879.00M | 1.08B | 993.00M | -7.9% | |
| Interest Expense | (536.00M) | (726.00M) | (1.49B) | (1.65B) | (1.42B) | -14.2% | |
| Other Income/Expenses (Net) | -1.48B | -862.00M | -1.21B | -667.00M | -842.00M | 26.2% | |
Income Before Tax | 8.84B | 7.66B | 6.24B | 7.00B | 7.27B | 3.9% | |
| Income Tax Expense | (1.11B) | (703.00M) | (284.00M) | (657.00M) | (547.00M) | -16.7% | |
Net Income | 7.72B | 6.95B | 6.00B | 6.33B | 6.74B | 6.3% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $20 | $18 | $16 | $17 | $18 | 7.2% | |
| Weighted Avg Shares Outstanding | 394.00M | 392.00M | 386.00M | 382.00M | 376.00M | -1.6% | |
| Weighted Avg Shares Outstanding (Diluted) | 397.00M | 394.00M | 388.00M | 383.00M | 377.00M | -1.6% | |
EBITDA | 11.97B | 11.94B | 11.20B | 11.80B | 11.47B | -2.8% |
Explore TMO
TMO in the Healthcare
Mega Cap